Lupin Launches Generic Drugs in US: USFDA Approval
By Rediff Money Desk, New Delhi Jun 03, 2024 17:11
Lupin has received USFDA approval to launch generic Doxycycline for Injection and Letermovir Tablets in the US market, targeting a combined annual market value of USD 362 million.
![Lupin Launches Generic Drugs in US: USFDA Approval](https://im.rediff.com/money/2021/feb/08lupin-1.jpg)
New Delhi, Jun 3 (PTI) Drug maker Lupin on Monday said it has launched a generic medication used to treat or prevent bacterial infections in the US market.
The company has launched Doxycycline for Injection USP (100 single-dose vial) in the US post approvals from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a statement.
The company's product is a generic equivalent of Pfizer Inc's Vibramycin for Injection which is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT April 2024 data, Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the US.
Lupin said it has also received tentative approval from the USFDA for its abbreviated new drug application for Letermovir Tablets, 240 mg and 480 mg.
The product is the generic equivalent of Merck Sharp & Dohme LLC's Prevymis tablets (240 mg and 480 mg).
Letermovir tablets are indicated to prevent disease caused by a virus called cytomegalovirus (CMV).
As per the IQVIA MAT April 2024 data, Letermovir tablets had an estimated annual sale of USD 314 million in the US.
Shares of the company on Monday ended 0.25 per cent at Rs 1,583.95 apiece on the BSE.
The company has launched Doxycycline for Injection USP (100 single-dose vial) in the US post approvals from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a statement.
The company's product is a generic equivalent of Pfizer Inc's Vibramycin for Injection which is indicated to reduce the development of drug-resistant bacteria.
As per the IQVIA MAT April 2024 data, Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the US.
Lupin said it has also received tentative approval from the USFDA for its abbreviated new drug application for Letermovir Tablets, 240 mg and 480 mg.
The product is the generic equivalent of Merck Sharp & Dohme LLC's Prevymis tablets (240 mg and 480 mg).
Letermovir tablets are indicated to prevent disease caused by a virus called cytomegalovirus (CMV).
As per the IQVIA MAT April 2024 data, Letermovir tablets had an estimated annual sale of USD 314 million in the US.
Shares of the company on Monday ended 0.25 per cent at Rs 1,583.95 apiece on the BSE.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 17.90 ( -3.35)
- 166585989
- Alstone Textiles
- 0.75 (+ 8.70)
- 47681821
- GTL Infrastructure
- 3.27 (+ 4.81)
- 44040612
- Visagar Financial
- 0.91 (+ 12.35)
- 29755394
- YES Bank Ltd.
- 23.70 (+ 0.77)
- 22163699
MORE NEWS
![Piyush Goyal:...](https://im.rediff.com/80-80/money/2017/jan/11goyal.jpg)
Piyush Goyal: Govt Committed to Industrial...
Hyderabad, Jun 30 (PTI) Union Commerce Minister Piyush Goyal on Sunday said the...
![Piyush Goyal:...](https://im.rediff.com/80-80/money/2019/jan/23piyush.jpg)
Piyush Goyal: Govt Committed to Industrial...
Hyderabad, Jun 30 (PTI) Union Commerce Minister Piyush Goyal on Sunday said the...
![Indian Economy...](https://im.rediff.com/80-80/money/2020/nov/22economy.jpg)
Indian Economy Growth: Exports, Manufacturing &...
Mumbai, June 30 (PTI) Healthy increase in the country's exports, improvement in the...